Sumitomo Pharma Co., Ltd.: Schizophrenia trials

The registry lists 41 Schizophrenia studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 28 have results posted.

Phase 1 11Phase 2 5Phase 3 22Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With SchizophreniaCompletedNCT03627195Phase 1Results posted
• Long-term Study of DSP-5423P in Patients With SchizophreniaCompletedNCT02335658Phase 3Results posted
• Confirmatory Study of DSP-5423P in Patients With SchizophreniaCompletedNCT02287584Phase 3Results posted
• Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human SubjectsCompletedNCT02174523Phase 1Results posted
• A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy SubjectsCompletedNCT02174510Phase 1Results posted
• A Clinical Trial of Lurasidone in Treatment of SchizophreniaCompletedNCT02002832Phase 3Results posted
• Pediatric Open-Label Extension StudyCompletedNCT01914393Phase 3Results posted
• Pediatric Schizophrenia Efficacy and Safety StudyCompletedNCT01911429Phase 3Results posted
• Lurasidone Low-Dose - High-Dose Study StudyCompletedNCT01821378Phase 3Results posted
• Lurasidone Pediatric Pharmacokinetics StudyCompletedNCT01620060Phase 1Results posted
• Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With SchizophreniaCompletedNCT01614912Phase 3Results posted
• A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With SchizophreniaCompletedNCT01614899Phase 3Results posted
• A Twelve Week, Open Label Extension Study in Patients With SchizophreniaCompletedNCT01566162Phase 3Results posted
• Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With RisperidoneCompletedNCT01516424Phase 3Results posted
• Lurasidone Extended Use StudyCompletedNCT01485640Phase 3Results posted
• PEARL Schizophrenia MaintenanceCompletedNCT01435928Phase 3Results posted
• A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective DisorderCompletedNCT01143090Phase 3Results posted
• A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsCompletedNCT01143077Phase 3Results posted
• Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.CompletedNCT00790192Phase 3Results posted
• Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic SchizophreniaCompletedNCT00789698Phase 3Results posted
• Study of SM-13496 (Lurasidone HCl) in Patients With SchizophreniaCompletedNCT00711269Phase 3Results posted
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable SchizophreniaCompletedNCT00641745Phase 3Results posted
• Lurasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaCompletedNCT00615433Phase 3Results posted
• Lurasidone HCl: A Phase 3 Study of Patients With Acute SchizophreniaCompletedNCT00549718Phase 3Results posted
• A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of SchizophreniaCompletedNCT00088634Phase 2Results posted
• A Study to Test the Safety and Tolerability of a New Medication in the Treatment of SchizophreniaCompletedNCT00088621Phase 2Results posted
• A Comparison of Study Drug With Placebo and Haloperidol in Patients With SchizophreniaCompletedNCT00044044Phase 2Results posted
• Safety and Tolerability Study of Drug to Treat SchizophreniaCompletedNCT00044005Phase 2Results posted
• A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanTerminatedNCT05359081Phase 3
• The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From OlanzapineTerminatedNCT05213143Phase 4
• The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With SchizophreniaCompletedNCT05011669Phase 4
• A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension PhaseTerminatedNCT04825860Phase 2/3
• The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia PatientsCompletedNCT04432688
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With SchizophreniaCompletedNCT04325737Phase 1
• Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia PatientsTerminatedNCT03784222Phase 4
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).CompletedNCT03370640Phase 1
• Digoxin Drug-Drug Interaction With Lurasidone HClCompletedNCT01082289Phase 1
• Midazolam Drug-Drug Interaction Study With Lurasidone HClCompletedNCT01082263Phase 1
• The Bioequivalence Of Two Different Lurasidone Formulations In PatientsCompletedNCT01082250Phase 1
• Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HClCompletedNCT01074632Phase 1
• Lithium Drug-Drug Interaction Study With Lurasidone HClCompletedNCT01074073Phase 1